Ongaro, Alessia, De Mattei, Monica, Pellati, Agnese, Caruso, Angelo, Ferretti, Stefano, Masieri, Federica, Fotinidi, Maria, Farina, Ilaria, Trotta, Francesco and Padovan, Melissa (2008) Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFalpha therapy in rheumatoid arthritis? Rheumatology international, 28 (9). pp. 901-8. ISSN 0172-8172

Full text not available from this repository.

Abstract

In this study we analyzed whether the polymorphisms 676T>G in the tumor necrosis factor receptor (TNFR) II gene and -308G>A in the TNFalpha promoter gene may influence the response grading to anti-TNFalpha therapy in rheumatoid arthritis. We enrolled and genotyped 105 RA patients treated with etanercept (n = 55), infliximab (n = 40) and adalimumab (n = 10) for 1 year. The clinical response was evaluated according to the ACR criteria every 3 months. Patients with TNFRII 676TG genotype was significantly associated with lower ACR response compared with 676TT genotype, at 3 (OR 3.78 95% CI 1.07-13.31) and 12 months (OR 4.30 95% CI 1.16-15.99) of treatment. No significant association between TNFalpha -308G>A polymorphism and the clinical response was found. TNFRII 676TG genotype is associated with a lower response to anti-TNFalpha therapy, independently from the specific agent used. This polymorphism could become a useful genetic marker for predicting the different response grading to anti-TNFalpha therapy.

Item Type:	Article
Uncontrolled Keywords:	Rheumatoid arthritis, Anti-TNFα therapy, TNFRII 676T<G polymorphism
Subjects:	Q Science > Q Science (General) R Medicine > R Medicine (General)
Divisions:	Faculty of Health & Science > Department of Science & Technology
Depositing User:	Federica Masieri
Date Deposited:	23 Feb 2021 09:18
Last Modified:	01 Mar 2021 16:08
URI:	https://oars.uos.ac.uk/id/eprint/1634

Actions (login required)

View Item